Bilcare (BI)₹74.29+1.63%Healthcare Research, Analytics & Technology
In the Jun 2026 quarter (consolidated), Bilcare reported sales of ₹226 Cr, up 21.6% from Jun 2025, and net profit of ₹14.96 Cr. For the year to Mar 2026, sales were ₹733 Cr and net profit −₹16.95 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 189 | 175 | 200 | 193 | 202 | 197 | 193 | 186 | 178 | 181 | 188 | 226 |
| Expenses | 173 | 158 | 207 | 175 | 194 | 187 | 186 | 175 | 175 | 168 | 171 | 189 |
| Operating Profit | 17.05 | 17.05 | −8.01 | 19.05 | 8.02 | 11.02 | 8.02 | 11.03 | 3.01 | 13.04 | 17.05 | 37.11 |
| OPM % | 9.0% | 10.0% | −4.1% | 10.0% | 3.8% | 5.0% | 4.0% | 6.0% | 1.9% | 7.0% | 9.1% | 16.1% |
| Other Income | 1.01 | 4.02 | 9.03 | 4.02 | −6.03 | −6.02 | 21.09 | 6.03 | 4.02 | 3.01 | 12.04 | 0.00 |
| Interest | 20.01 | 21.02 | 23.02 | 21.02 | 24.01 | 19.01 | 19.01 | 19.02 | 18.99 | 17.02 | 17.99 | 18.01 |
| Depreciation | 9.99 | 10.99 | 12.99 | 11.99 | 10.99 | 11.99 | 4.99 | 12.01 | 11.99 | 4.99 | 4.99 | 4.01 |
| Profit before tax | −12.99 | −9.99 | −34.97 | −9.99 | −32.98 | −26.96 | 5.99 | −12.98 | −23.98 | −5.99 | 6.99 | 14.97 |
| Tax % | −5.0% | 33.9% | −44.1% | 54.9% | −10.1% | −40.1% | −119.1% | −25.1% | −1.0% | 3.0% | −13.1% | −1.0% |
| Exceptional items | −10.01 | 0.00 | 4.01 | 0.00 | −10.02 | −10.01 | 14.03 | 0.00 | 0.00 | −2.01 | −2.01 | −2.01 |
| Net Profit | −11.96 | −13.95 | −19.92 | −14.95 | −29.89 | −15.94 | 11.97 | −9.98 | −22.94 | −5.99 | 7.98 | 14.96 |
| EPS (Rs) | −3.23 | −2.92 | −4.64 | −2.72 | −6.83 | −3.05 | 7.49 | −1.62 | −5.26 | 0.42 | 5.70 | 5.40 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,595 | 2,626 | 2,771 | 2,989 | 1,823 | 621 | 843 | 980 | 746 | 786 | 733 | 771 |
| Expenses | 2,391 | 2,440 | 2,611 | 2,821 | 1,780 | 571 | 783 | 924 | 706 | 742 | 688 | 702 |
| Operating Profit | 207 | 191 | 161 | 171 | 45.08 | 51.16 | 60.17 | 57.18 | 39.07 | 45.11 | 44.12 | 70.21 |
| OPM % | 8.1% | 7.0% | 6.0% | 6.0% | 2.5% | 8.0% | 7.0% | 6.0% | 5.0% | 6.0% | 6.0% | 9.1% |
| Other Income | −87.36 | 107 | 298 | 59.24 | 255 | 45.16 | 44.20 | 238 | 16.06 | 12.05 | 26.08 | 19.07 |
| Interest | 151 | 176 | 249 | 283 | 174 | 76.03 | 69.01 | 59.99 | 82.05 | 82.04 | 71.98 | 72.01 |
| Depreciation | 164 | 177 | 416 | 378 | 239 | 45.98 | 39.01 | 38.01 | 44.98 | 45.98 | 19.99 | 25.98 |
| Profit before tax | −194 | −55.94 | −207 | −433 | −114 | −24.97 | −3.99 | 196 | −71.94 | −70.88 | −20.99 | −8.01 |
| Tax % | −58.1% | 42.0% | −4.0% | 5.0% | −13.1% | −55.1% | 3.0% | 73.9% | −18.1% | −21.1% | −19.1% | — |
| Exceptional items | −98.08 | 45.05 | 237 | −1.01 | 195 | 21.04 | 30.04 | 82.06 | −1.01 | −4.01 | −4.01 | −6.03 |
| Net Profit | −81.76 | −79.74 | −198 | −452 | −98.72 | −10.97 | −3.99 | 49.82 | −58.77 | −55.87 | −16.95 | −5.99 |
| EPS (Rs) | −36.16 | −36.03 | −85.64 | −193.88 | −44.10 | −8.97 | −5.37 | 6.41 | −14.15 | −12.26 | 0.74 | 6.26 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.10 | 24.08 | 24.09 | 24.06 | 24.07 | 24.08 | 24.09 | 24.09 | 24.09 | 24.07 | 24.09 | 24.09 |
| Reserves | 1,072 | 689 | 589 | 375 | −92.60 | 85.00 | 62.98 | 52.05 | 507 | 474 | 445 | 173 |
| Borrowings | 2,313 | 2,122 | 2,015 | 2,088 | 2,267 | 708 | 677 | 691 | 639 | 757 | 683 | 621 |
| Other Liabilities | 937 | 790 | 834 | 917 | 892 | 298 | 301 | 364 | 426 | 316 | 267 | 26.12 |
| Total Liabilities | 4,346 | 3,623 | 3,461 | 3,405 | 3,089 | 1,114 | 1,066 | 1,130 | 1,595 | 1,570 | 1,419 | 845 |
| Fixed Assets | 1,926 | 2,433 | 2,404 | 2,181 | 2,004 | 534 | 494 | 465 | 1,046 | 1,038 | 949 | 433 |
| CWIP | 217 | 161 | 149 | 169 | 78.72 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 3.99 | 7.97 |
| Investments | 0.00 | 1.01 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 8.01 | 11.01 | 14.01 |
| Other Assets | 2,203 | 1,029 | 907 | 1,054 | 1,006 | 579 | 572 | 664 | 547 | 523 | 454 | 388 |
| Inventories | 413 | 399 | 332 | 374 | 370 | 77.10 | 101 | 136 | 84.14 | 106 | 117 | 115 |
| Trade receivables | 924 | 249 | 208 | 291 | 310 | 108 | 154 | 220 | 189 | 150 | 119 | 108 |
| Cash & equivalents | 156 | 110 | 124 | 99.96 | 90.95 | 63.93 | 56.92 | 39.94 | 30.99 | 35.99 | 14.99 | 5.99 |
| Total Assets | 4,346 | 3,623 | 3,461 | 3,405 | 3,089 | 1,114 | 1,066 | 1,130 | 1,595 | 1,570 | 1,419 | 845 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −316 | 178 | 301 | 98.46 | 207 | 257 | 72.26 | 41.19 | −7.03 | 62.21 | 85.27 | 129 |
| Cash from investing activity | 247 | −357 | −129 | −203 | −104 | 1,307 | 1.99 | −3.99 | 35.95 | −106 | 80.94 | −5.99 |
| Cash from financing activity | 120 | 150 | −156 | 91.26 | −103 | −1,607 | −83.31 | −55.20 | −19.08 | 36.11 | −170 | −132 |
| Net cash flow | 50.03 | −32.02 | 16.02 | −13.02 | −1.01 | −35.05 | −9.01 | −18.02 | 10.01 | −7.01 | −3.01 | −10.01 |
| Capex | 0.00 | 201 | 145 | 215 | 115 | 0.00 | 6.03 | 4.71 | 0.00 | 120 | 22.62 | 10.85 |
| Free cash flow | −74.10 | −12.01 | 165 | −115 | 91.13 | 1,570 | 69.10 | 37.05 | 11.02 | −34.04 | 140 | 120 |
| CFO / OP % | −169.9% | 85.1% | 173.1% | 75.1% | 148.1% | 828.0% | 141.1% | 78.1% | −6.0% | 162.1% | 193.0% | 284.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 126 | 36 | 30 | 39 | 39 | 23 | 91 | 96 | 71 | 74 | 56 | 55 |
| Inventory days | 105 | 108 | 84 | 90 | 82 | 28 | 90 | 83 | 42 | 77 | 80 | 86 |
| Days payable | 93 | 86 | 81 | 102 | 71 | 35 | 93 | 102 | 77 | 70 | 57 | 70 |
| Cash conversion cycle | 138 | 58 | 33 | 26 | 50 | 16 | 89 | 77 | 35 | 81 | 79 | 70 |
| Working capital days | 124 | 4 | −12 | −151 | −157 | −3 | −20 | −11 | −11 | 11 | −6 | 27 |
| ROCE % | 1.0% | 2.0% | 2.0% | −8.0% | −6.0% | −9.0% | 3.0% | 3.0% | 3.0% | 1.0% | 1.0% | 6.0% |
For the Jun 2026 quarter, Bilcare reported sales of ₹226 Cr, up 21.6% year on year and net profit of ₹14.96 Cr. The operating margin was 16.1%.
Bilcare's sales for the year to Mar 2026 were ₹733 Cr; over the last twelve months they were ₹771 Cr.
Net profit for the year to Mar 2026 was −₹16.95 Cr, and −₹5.99 Cr over the last twelve months. Earnings per share over the same trailing period were ₹6.26.
Bilcare reported borrowings of ₹621 Cr at Mar 2026, against cash and equivalents of ₹5.99 Cr.
Cash from operations was ₹129 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹120 Cr.